Roivant Sciences
Developing transformative medicines faster by building technologies and developing talent in creative ways.
| EUR | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 132 % | 11 % | 104 % | (77 %) | 1 % | 49 % | 1061 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2713 %) | (1807 %) | (799 %) | (4365 %) | (4679 %) | (2995 %) | (140 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1529 %) | (1647 %) | 3485 % | (592 %) | (3064 %) | (2391 %) | (150 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 874 % | 857 % | 402 % | 1895 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Roivant Sciences is a biopharmaceutical company dedicated to developing and delivering innovative medicines and technologies to improve patient health. The company focuses on maximizing the potential of promising drug candidates, particularly in the areas of genetic disorders and RNA therapeutics. Roivant operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources.
Roivant serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical companies. The company employs a unique business model that combines in-house product development with strategic partnerships. This approach allows Roivant to build a robust pipeline of drug candidates and leverage cutting-edge technologies to address various medical needs.
One of Roivant's key subsidiaries, Genevant, specializes in RNA therapeutics. Genevant uses proprietary delivery platforms to develop treatments based on mRNA (messenger RNA), RNAi (RNA interference), and gene editing. These technologies enable the company to select the most effective approach for treating specific diseases.
Roivant generates revenue through the development and commercialization of its drug candidates. This includes licensing agreements, partnerships with other pharmaceutical companies, and the sale of approved drugs. By rapidly advancing its drug pipeline and forming strategic alliances, Roivant aims to bring innovative treatments to market more quickly and efficiently.
In summary, Roivant Sciences is a forward-thinking biopharmaceutical company that leverages technology and strategic partnerships to develop innovative medicines. The company operates in the biopharmaceutical market, serving patients, healthcare providers, and pharmaceutical companies, and generates revenue through drug development and commercialization.
Keywords: biopharmaceutical, drug development, RNA therapeutics, genetic disorders, mRNA, RNAi, gene editing, partnerships, innovative medicines, healthcare.
Tech stack
Investments by Roivant Sciences
Edit
